Catalysts / CLDX
Upcoming FDA decisions and readouts we track for Celldex Therapeutics, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for Celldex Therapeutics (CLDX, listed on Nasdaq). All of them concern Barzolvolimab (Chronic spontaneous urticaria (anti-KIT); Atopic dermatitis; Chronic spontaneous urticaria).
First on the list: the Phase 3 readout for Barzolvolimab (Chronic spontaneous urticaria (anti-KIT)), guided by the company to Sep 2026. The furthest-out event tracked is 2027. By stage, the upcoming rows are 1 Phase 2 readout, 1 Phase 3 readout and 1 Regulatory submission.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: How to read a Phase 3 topline readout; Clinical trial phases explained: Phase 1 to Phase 4; NDA vs BLA: the two kinds of US drug application.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics CLDX · Nasdaq | Barzolvolimab | Chronic spontaneous urticaria (anti-KIT) | Sep 2026 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Celldex Therapeutics CLDX · Nasdaq | Barzolvolimab | Atopic dermatitis | Late 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Celldex Therapeutics CLDX · Nasdaq | Barzolvolimab | Chronic spontaneous urticaria | 2027 company guidance |
Regulatory submission | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList